{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:29:49Z","timestamp":1707524989225},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,20]]},"DOI":"10.7759\/cureus.36444","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T05:37:29Z","timestamp":1679377049000},"source":"Crossref","is-referenced-by-count":0,"title":["The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis"],"prefix":"10.7759","author":[{"given":"Arvind","family":"Chopra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagnath","family":"Khadke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjit","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toktam","family":"Kianifard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Venugopalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihir","family":"Gharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun J","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007, 369:1379-90. 10.1016\/S0140-6736(07)60635-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68 Suppl 2","author":"Sieper J","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, et al.. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009, 68 Suppl 2:ii1-44. 10.1136\/ard.2008.104018","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"68","author":"Ward MM","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, et al.. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2016, 68:282-98. 10.1002\/art.39298","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.injr.2015.04.002","article-title":"Disease burden of rheumatic diseases in India: COPCORD perspective","volume":"10","author":"Chopra A","year":"2015","unstructured":"Chopra A. Disease burden of rheumatic diseases in India: COPCORD perspective. Indian J Rheumatol. 2015, 10:70-7. 10.1016\/j.injr.2015.04.002","journal-title":"Indian J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.injr.2012.04.005","article-title":"Biosimilar DMARD in rheumatology: a general perspective with focus on India","volume":"7","author":"Chopra A","year":"2012","unstructured":"Chopra A, Shankar S. Biosimilar DMARD in rheumatology: a general perspective with focus on India. Indian J Rheumatol. 2012, 7:89-96. 10.1016\/j.injr.2012.04.005","journal-title":"Indian J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203198","article-title":"Biosimilars to treat inflammatory arthritis: the challenge of proving identity","volume":"72","author":"Kay J","year":"2013","unstructured":"Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013, 72:1589-93. 10.1136\/annrheumdis-2012-203198","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/BS.S75573","article-title":"Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197","volume":"1","author":"Bandyopadhyay S","year":"2014","unstructured":"Bandyopadhyay S, Mahajan M, Mehta T, et al.. Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Biosimilars. 2014, 1:1-18. 10.2147\/BS.S75573","journal-title":"Biosimilars"},{"key":"ref8","unstructured":"Exemptia\u2122 (adalimumab). (2023). Accessed. February 23, 2023: https:\/\/exemptia.com\/adalimumab-india.html."},{"key":"ref9","article-title":"Our experience with anti-TNF therapy - a choice between the devil and the deep sea","volume":"9","author":"Chopra A","year":"2005","unstructured":"Chopra A, Lagoo-Joshi V, Kunjeer V. Our experience with anti-TNF therapy - a choice between the devil and the deep sea. APLAR J Rheumatol. 2005, 9:A208.","journal-title":"APLAR J Rheumatol"},{"key":"ref10","unstructured":"Clinical effectiveness of adalimumab (Exemptia\u2122) in patients suffering from symptomatic ankylosing spondylitis (AS) under supervised standard rheumatology care. (2023). Accessed. February 23, 2023: https:\/\/ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=19498&EncHid=&modid=&compid=%27,%2719498det%27."},{"key":"ref11","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994, 21:2286-91.","journal-title":"J Rheumatol"},{"key":"ref12","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin A","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994, 21:2281-5.","journal-title":"J Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas C","year":"2009","unstructured":"Lukas C, Landew\u00e9 R, Sieper J, et al.. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009, 68:18-24. 10.1136\/ard.2008.094870","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado P","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011, 70:47-53. 10.1136\/ard.2010.138594","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.injr.2012.04.009","article-title":"Validation and usefullness of Indian version (CRD Pune) health assessment questionnaire: drug trials, community practice and COPCORD Bhigwan population study (1994-2012)","volume":"7","author":"Chopra A","year":"2012","unstructured":"Chopra A, Saluja M. Validation and usefullness of Indian version (CRD Pune) health assessment questionnaire: drug trials, community practice and COPCORD Bhigwan population study (1994-2012). Indian J Rheumatol. 2012, 7:74-82. 10.1016\/j.injr.2012.04.009","journal-title":"Indian J Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199360","article-title":"Tuberculin skin test and QuantiFERON-Gold In Tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting","volume":"13","author":"Chandrasekaran P","year":"2018","unstructured":"Chandrasekaran P, Mave V, Thiruvengadam K, et al.. Tuberculin skin test and QuantiFERON-Gold In Tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting. PLoS One. 2018, 13:e0199360. 10.1371\/journal.pone.0199360","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados M","year":"1991","unstructured":"Dougados M, van der Linden S, Juhlin R, et al.. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991, 34:1218-27. 10.1002\/art.1780341003","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.10.005","article-title":"Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis","volume":"28","author":"Poddubnyy D","year":"2014","unstructured":"Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014, 28:807-18. 10.1016\/j.berh.2014.10.005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos X","year":"2005","unstructured":"Baraliakos X, Listing J, Brandt J, et al.. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther. 2005, 7:R439-44. 10.1186\/ar1693","journal-title":"Arthritis Res Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde D","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al.. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006, 54:2136-46. 10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000025","article-title":"Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials","volume":"26","author":"Louie GH","year":"2014","unstructured":"Louie GH, Ward MM. Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials. Curr Opin Rheumatol. 2014, 26:145-50. 10.1097\/BOR.0000000000000025","journal-title":"Curr Opin Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204102","article-title":"Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries","volume":"73","author":"Zavada J","year":"2014","unstructured":"Zavada J, Dixon WG, Askling J. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis. 2014, 73:628. 10.1136\/annrheumdis-2013-204102","journal-title":"Ann Rheum Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study","volume":"52","author":"van der Heijde D","year":"2005","unstructured":"van der Heijde D, Baraf HS, Ramos-Remus C, et al.. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005, 52:1205-15. 10.1002\/art.20985","journal-title":"Arthritis Rheum"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper J","year":"2014","unstructured":"Sieper J, Lenaerts J, Wollenhaupt J, et al.. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014, 73:101-7. 10.1136\/annrheumdis-2012-203201","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30013-X","article-title":"IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial","volume":"1","author":"Xu H","year":"2019","unstructured":"Xu H, Li Z, Wu J, et al.. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. Lancet Rheumatol. 2019, 1:35-43. 10.1016\/S2665-9913(19)30013-X","journal-title":"Lancet Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11067","article-title":"Real-life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: the adalimumab biosimilar patient registry data","volume":"1","author":"Kapoor S","year":"2019","unstructured":"Kapoor S, Kaushik VV, Jain R, Rao VK, Gharia M. Real-life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: the adalimumab biosimilar patient registry data. ACR Open Rheumatol. 2019, 1:480-4. 10.1002\/acr2.11067","journal-title":"ACR Open Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2018.16.1.83","article-title":"Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis","volume":"16","author":"Midha V","year":"2018","unstructured":"Midha V, Mahajan R, Mehta V, Narang V, Singh A, Kaur K, Sood A. Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis. Intest Res. 2018, 16:83-9. 10.5217\/ir.2018.16.1.83","journal-title":"Intest Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester GR","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013, 72:517-24. 10.1136\/annrheumdis-2011-201244","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.011023","article-title":"Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review","volume":"62","author":"Keller C","year":"2003","unstructured":"Keller C, Webb A, Davis J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis. 2003, 62:1128-32. 10.1136\/ard.2003.011023","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.14.21266244","article-title":"Sustained effects of short-term adalimumab biosimilar (ZRC-3197) therapy on outcome measures in ankylosing spondylitis","author":"Chopra A","year":"2023","unstructured":"Chopra A, Khadke N, Saluja M, Kianifard T, Gharia M, Venugopalan A. Sustained effects of short-term adalimumab biosimilar (ZRC-3197) therapy on outcome measures in ankylosing spondylitis. medRxiv. 2023, 10.1101\/2021.11.14.21266244","journal-title":"medRxiv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/141024-the-long-term-effects-of-short-period-adalimumab-biosimilar-usage-in-ankylosing-spondylitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:49Z","timestamp":1707508669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/141024-the-long-term-effects-of-short-period-adalimumab-biosimilar-usage-in-ankylosing-spondylitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.36444","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,20]]}}}